Pharmacogenetics and interindividual variability in drug response: Cytochrome P-450 2C9 and coumarin anticoagulants;Pharmacogénétique et variabilité inter individuelle de la réponse aux traitements: L'exemple du cytochrome P-450 2C9 et des anticoagulants coumariniques

Bulletin de l'Academie Nationale de Medecine

Volumn 190, Issue 1, 2006, Pages 37-53

  Becquemont, Laurent ^a   Verstuyft, Céline ^a   Jaillon, Patrice ^a   Boulu, Roger ^b   Larcan, Alain ^b   Godeau, Pierre ^b   Launois, Bernard ^b   Sraer, Jean Daniel ^b   Nordmann, Roger ^b   Queneau, Patrice ^b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b Université Paris XI et Assistance Publique Hôpitaux de Paris ^*

Author keywords

Anticoagulants; Coumarins; Cytochrome P 450 enzyme system; Pharmacogenetics

Indexed keywords

EID: 33745796366     PISSN: 00014079     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0001-4079(19)33352-7     Document Type: Review

References (24)

1. BONICKE R., REIF W. - Enzymatische inaklivierung von isonicotinsaure hydrazide im meuschlichen und tierischen Organismus - Arch. Exp. Pathol. Pharmakol., 1953, 220, 321-33.
2. HUGHES H.B., BIEHL J.P., JONES A.P, SCHMIDT L.H. - On the metabolic fate of isoniazid J. Pharmacol Exp. Therap, 1953, 109, 444-452.
3. HUGHES H.B., BIEHL J.P., JONES A.P., SCHMIDT L.H. - Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis - Am. Rev. Tuberc, 1954, 70, 266-273.
4. CARSON P.E., FLANAGAN C.L, ICKES C.E., ALVONG A.S. - Enzymatic deficiency in primaquine sensitive erythrocytes, Science, 1956, 124, 484-485.
5. KALOW W, GENEST K. - A method for the detection of atypical forms of human serum cholinesterase. Determination of dibucaine numbers, Can. K. Biochem. Physiol., 1957, 35, 339-346.
6. NEBERT D.W., RUSSELL D.W. - Clinical importance of the cytochromes P450 - Lancet, 2002, 360, 1155-1162.
7. LEE C.R., GOLDSTEIN J.A., PIEPER J.A - Cytochrome P450 2C9 phymorphisms: a comprehensive review of the in-vitro and human data -Pharmacogenetics, 2002, 12, 251-263.
8. YANG J.Q., MORIN S., VERSTUYFT C., FAN L.A., ZHANG Y., XU C.D., BARBU V. et al - Frequency of cytochrome P450 2C9 allelic variants in the Chinese and french populations Fund. Clin. Pharmacol., 2003, 17, 373-376.
9. PEDERSEN R.S., VERSTUYFT C., BECQUEMONT L., JAILLON P., BROSEN K. - Cytochrome P450 2C9 (CYP2C9) genotypes in a nordic population in Denmark - Basic Clin. Pharmacol. Toxicol., 2004, 94, 151-152.
10. THUSSEN H., FLINOIS J.P, BEAUNE P. - Cytochrome P450 2C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes - Drug Metab. Dispos., 2000, 28, 1284-1290.
11. STEWARD D.J., HAINING R.L., HENNE K.R., DAVIS G., RUSHMORE T.H., TRAGER W.F. et al. - Genetic association between sensitivity to warfarin and expression of CYP2C9*3 -Pharmacogenetics, 1997, 7, 361-367.
12. THUSSEN H., VERKOOIJEN I., FRANK H. - The possession of the CYP 2C9*3 allele is associated with low dose requirement of acenocoumarol - Pharmacogenetics, 2000, 10, 757-760.
13. OGG M.S., BRENNAN P., MEADE T., HUMPHRIES S.E. - CYP 2C9*3 allelic variant and bleeding complications. Lancet, 1999, 554, 1124.
14. VERSTUYFT C., MORIN S., ROBERT A., LORIOT M.A., BEAUNE P., JAILLON P. et al. - Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolisers. Pharmacogenetics, 2001, 11, 735-737.
15. VERSTUYFT C., ROBERT A., MORIN S., LORIOT M.A, FLAHAUT A., BEAUNE P., et al. - Genetic and environmental risk factors for oral anticoagulant overdose - Eur. J. Clin. Pharmacol., 2003, 58, 739-745.
16. MORIN S., BODIN L., LORIOT M.A., THIJSSEN H.H.W., ROBERT A., STRABACH S. et al. - Pharmacogenetics of acenocoumarol pharmacodynamics - Clin. Pharmacoi. Ther., 2004, 75, 403-414.
17. D'ANDREA G., D'AMBRIOSO R.L., DI PERNA P., CHETTA M., SANTACROCE R. et al. - A polymorphism in the VKOR C1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood, 2005, 105, 645-649.
18. RIEDER M.J., REINER A.P., GAGA B.F., NICKERSON D.A., EBY C.S., MCLEOD H.L. et al. - Effect of VKORC1 Haplotypes ou transcriptional regulation and warfarin dose. NEJM, 2005, 352, 2285-2293.
19. BODIN L., VERSTUYFT C., TREGOUET D.A., ROBERT A., DUBERT L., FUNCK-BRENTANO C. et al. - Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxyde reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood, 2005, 106, 135-140.
20. OUTEINEH L., VERSTUYFT C., DESCOT C., DUBERT L., ROBERT A., JAILLON P. et al. - Vitamin K epoxyde reductase (VKORC) genetic polymorphism is associated to oral anticoagulant overdose. Thromb. Haemost., 2005, 94, 690-691.
21. VISSER L.E., VAN SHAIK R., VAN VLIET M., TRIENEKENS P.H., DESMET P.A., VULTO A.G. et al. - Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal antiinflammatory drugs and coumarin anticoagulants. Clin. Pharmacoi. Ther., 2005, 77, 479-485.
22. LENNARD L., VAN LOON J.A., WEINSHILBOUM R.M. - Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin. Pharmacol. Ther., 1989, 46, 149-154.
23. STANULLA M., SCHAEFFELER E., FLOHR T., CARLO G., SCHRAUDER A., ZIMMERMANN M. et al. - Thiopurine methyltransferase (TMPT) genotype and early treatment response to mercaptopurine in childhood acute hymphoblastic lenkenia. JAMA, 2005, 293, 1485-1489.
24. TERRA S.G., PAULY D.F., LEE C.R., PATTERSON J.H., ADAMS K.F., SCHOFIELD R.S. et al - β - adrenergic receptor polymorphisms and responses during titration of metoprohol controlled release/extended release in heart failure. Clin. Pharmacoi. Ther., 2005, 77, 127-137.